Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRINCIPEN '500' vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Infections of the respiratory tract,Genitourinary tract infections,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Skin and soft tissue infections,Prophylaxis for bacterial endocarditis (off-label)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
500 mg orally every 6 hours for 7-14 days for mild to moderate infections; for severe infections, 500 mg orally every 4 hours.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
0.5–1 hour; prolonged in renal impairment (up to 10 hours in anuria).
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Ampicillin is metabolized primarily by hydrolysis to penicilloic acid; hepatic metabolism is minimal.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal (90% unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
~20% bound to serum albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.2–0.3 L/kg; limited to extracellular fluid.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
IM: 100% (complete); PO: 30–60% (acid-labile, variable).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
For Cr Cl 30-50 m L/min: administer 500 mg every 8 hours; Cr Cl 10-30 m L/min: 500 mg every 12 hours; Cr Cl <10 m L/min: 500 mg every 24 hours.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No specific adjustment required for hepatic impairment; caution in severe hepatic disease due to potential risk of crystalluria.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
For children >1 month: 12.5-25 mg/kg/dose orally every 6 hours; maximum 2 g/day. For neonates: 25 mg/kg/dose every 8 hours.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Adjust based on renal function; monitor for crystalluria and superinfection; standard dosing if Cr Cl >50 m L/min.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No FDA black box warning.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Serious hypersensitivity reactions (anaphylaxis) may occur,Clostridium difficile-associated diarrhea (CDAD),Seizures may occur in patients with renal impairment or high doses,Prolonged use may result in superinfection,Risk of bleeding abnormalities with high doses
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to ampicillin, penicillins, or any component of the formulation,Infections caused by beta-lactamase-producing organisms
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid acidic beverages (e.g., fruit juices, soda) within 1 hour of taking ampicillin, as they may reduce absorption. Take on an empty stomach to maximize bioavailability. No specific dietary restrictions required.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. No evidence of teratogenicity in first trimester; theoretical risk of diarrhea or rash in neonates if administered near term.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Ampicillin is excreted into breast milk in low concentrations (M/P ratio ~0.05–0.2). Compatible with breastfeeding; may cause diarrhea or rash in infant. Monitor for gastrointestinal effects or sensitization.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Physiologic changes in pregnancy (increased plasma volume, renal clearance) may reduce serum ampicillin concentrations; consider higher doses (e.g., 500 mg every 6 hours) for standard infections, but no specific dose adjustment recommendations exist. Monitor clinical response.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Principen '500' (ampicillin) is a penicillin-class antibiotic with activity against gram-positive cocci (except penicillinase-producing staphylococci) and some gram-negative bacilli. Use caution in patients with penicillin allergy; cross-reactivity with cephalosporins occurs in ~1% of cases. Monitor for rash, which can be maculopapular (commonly in patients with mononucleosis) or urticarial. Dose adjustment required in renal impairment (Cr Cl <30 m L/min). Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. Avoid concurrent use with allopurinol due to increased risk of ampicillin rash.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take ampicillin exactly as prescribed, even if you feel better.,Take on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water.,Finish the entire course of treatment; do not stop early unless directed by your doctor.,Inform your doctor if you have a penicillin allergy, kidney disease, or mononucleosis.,Contact your doctor if you develop severe diarrhea, rash, or difficulty breathing.,Ampicillin may reduce the effectiveness of oral contraceptives; use additional birth control methods.,Store at room temperature away from moisture and heat.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRINCIPEN '500' vs ALFENTA, answered by our medical review team.
PRINCIPEN '500' is a Aminopenicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRINCIPEN '500' and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRINCIPEN '500' is: 500 mg orally every 6 hours for 7-14 days for mild to moderate infections; for severe infections, 500 mg orally every 4 hours.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRINCIPEN '500' and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRINCIPEN '500' is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. No evidence of teratogenicity in. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.